If Valeant gets approval on a couple of drugs, which is likely even odds, or at least one drug then development spending on the drug/drugs stops and production and sales starts. Valeant then has more money coming in then going out on the drug/drugs involved. Cash flow improves. The ability to roll-over expiring debt improves. The small problem becomes an even smaller problem.